{"title":"Factors associated with pulmonary function decline in patients with rheumatoid arthritis-associated interstitial lung disease","authors":"Takako Kawaguchi , Masahiro Tahara , Kei Yamasaki , Natsumi Tani , Yurie Kanda-Satoh , Takatoshi Aoki , Yoshiya Tanaka , Kazuhiro Yatera","doi":"10.1016/j.resinv.2025.06.017","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Antifibrotic drugs have recently been recommended for patients with interstitial lung disease with progressive pulmonary function decline. However, the clinical characteristics of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) with progressive pulmonary function decline, including the relationship with RA disease activity, are unclear.</div></div><div><h3>Methods</h3><div>This retrospective study included patients diagnosed with RA-ILD at our hospital from 2011 to 2019 for whom data on pulmonary function tests (PFTs) and chest high-resolution computed tomography (HRCT) were available. Factors associated with a percent forced vital capacity (%FVC) absolute decline were determined using multivariate regression analysis, and a scoring system based on the results of the multivariate logistic regression analysis was developed to identify patients with progressive RA-ILD with an absolute decline in %FVC of ≥5 %.</div></div><div><h3>Results</h3><div>A total of 92 patients were enrolled, and the multivariate regression analysis showed that older-age (β, −0.27; 95 % confidence interval [CI], −0.49 to −0.05), worse Disease Activity Score 28-erythrocyte sedimentation rate (DAS28-ESR) (β, −1.52; 95 % CI, −2.61 to −0.42), and HRCT modified-fibrosis score (FS) increase (β, −0.39; 95 % CI, −0.53 to −0.25) were negatively correlated with %FVC absolute change. The new scoring system to identify the progressive-RA-ILD patients based on five factors (advanced-age, male, increasing modified-FS, increasing ground-glass opacities, and worsening DAS28-ESR) showed an area under the curve of 0.830 (95 % CI, 0.731–0.929).</div></div><div><h3>Conclusions</h3><div>The scoring system combining five factors may be useful in estimating progressive-RA-ILD patients without conducting PFTs and help clinicians reconsider appropriate treatments with antifibrotic drugs and/or immunosuppressive therapies to control RA disease activity and suppress progressive pulmonary function decline.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 5","pages":"Pages 857-865"},"PeriodicalIF":2.4000,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory investigation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212534525000978","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Antifibrotic drugs have recently been recommended for patients with interstitial lung disease with progressive pulmonary function decline. However, the clinical characteristics of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) with progressive pulmonary function decline, including the relationship with RA disease activity, are unclear.
Methods
This retrospective study included patients diagnosed with RA-ILD at our hospital from 2011 to 2019 for whom data on pulmonary function tests (PFTs) and chest high-resolution computed tomography (HRCT) were available. Factors associated with a percent forced vital capacity (%FVC) absolute decline were determined using multivariate regression analysis, and a scoring system based on the results of the multivariate logistic regression analysis was developed to identify patients with progressive RA-ILD with an absolute decline in %FVC of ≥5 %.
Results
A total of 92 patients were enrolled, and the multivariate regression analysis showed that older-age (β, −0.27; 95 % confidence interval [CI], −0.49 to −0.05), worse Disease Activity Score 28-erythrocyte sedimentation rate (DAS28-ESR) (β, −1.52; 95 % CI, −2.61 to −0.42), and HRCT modified-fibrosis score (FS) increase (β, −0.39; 95 % CI, −0.53 to −0.25) were negatively correlated with %FVC absolute change. The new scoring system to identify the progressive-RA-ILD patients based on five factors (advanced-age, male, increasing modified-FS, increasing ground-glass opacities, and worsening DAS28-ESR) showed an area under the curve of 0.830 (95 % CI, 0.731–0.929).
Conclusions
The scoring system combining five factors may be useful in estimating progressive-RA-ILD patients without conducting PFTs and help clinicians reconsider appropriate treatments with antifibrotic drugs and/or immunosuppressive therapies to control RA disease activity and suppress progressive pulmonary function decline.